AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) will be releasing its earnings data after the market closes on Thursday, August 10th. Analysts expect AEterna Zentaris to post earnings of ($0.41) per share for the quarter.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.02. AEterna Zentaris had a negative return on equity of 425.52% and a negative net margin of 2,732.69%. The business had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.85 million. During the same period last year, the company earned ($0.37) earnings per share. AEterna Zentaris’s quarterly revenue was up 8.3% compared to the same quarter last year. On average, analysts expect AEterna Zentaris to post $-1.56 EPS for the current fiscal year and $-0.8 EPS for the next fiscal year.

Shares of AEterna Zentaris Inc. (AEZS) traded up 1.52% during mid-day trading on Monday, hitting $2.00. The company had a trading volume of 244,456 shares. The firm’s 50-day moving average price is $1.36 and its 200 day moving average price is $2.12. The company’s market capitalization is $28.67 million. AEterna Zentaris Inc. has a one year low of $0.78 and a one year high of $5.59.

A number of brokerages recently weighed in on AEZS. HC Wainwright set a $3.00 target price on shares of AEterna Zentaris and gave the stock a “buy” rating in a research note on Wednesday, July 5th. Maxim Group set a $2.00 target price on shares of AEterna Zentaris and gave the stock a “buy” rating in a research note on Monday, May 1st. Finally, Zacks Investment Research lowered shares of AEterna Zentaris from a “hold” rating to a “sell” rating in a research note on Friday, May 12th.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at

AEterna Zentaris Company Profile

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Earnings History for AEterna Zentaris (NASDAQ:AEZS)

Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with's FREE daily email newsletter.